Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR G
Go back to Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR G| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 528.90 -17.22 (3.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $546.12 | 52 Week High | $134.71 | |||
| Open | $529.64 | 52 Week Low | $73.31 | |||
| Day High | $535.00 | P/E | N/A | |||
| Day Low | $520.20 | EPS | $-1.98 | |||
| Volume | 1,121,341 | |||||
